|
業務類別
|
Drug Manufacturers - Specialty & Generic |
|
業務概覽
|
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada. |
| 公司地址
| 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668 |
| 電話號碼
| +81 332782306 |
| 傳真號碼
| +81 332782268 |
| 公司網頁
| https://www.takeda.com |
| 員工數量
| 47029 |
| Dr. Andrew S. Plump, M.D.,PhD |
Director and President, Research and Development |
日圓 12.00M |
17/06/2026 |
| Mr. Marcello Agosti |
Interim Head, Strategy and Portfolio Development |
-- |
17/06/2026 |
| Ms. Teresa Marie Bitetti |
President, Global Oncology Business Unit |
-- |
17/06/2026 |
| Mr. Milano Furuta |
Director and Chief Financial Officer |
日圓 119.00M |
17/06/2026 |
| Ms. Julie Kim |
Chief Executive Officer, President and Director |
-- |
17/06/2026 |
| Mr. Giles Platford |
President, International Business Unit |
-- |
17/06/2026 |
| Ms. Lauren Duprey |
Chief Transformation Officer |
-- |
17/06/2026 |
| Mr. Gabriele Ricci |
Chief Data and Technology Officer |
-- |
17/06/2026 |
| Ms. Akiko Amakawa |
Chief Executive Officer Chief of Staff |
-- |
17/06/2026 |
| Ms. Asuka Miyabashira |
President, Japan Pharma Business Unit |
-- |
17/06/2026 |
| Ms. Elaine Shannon |
President, Global Supply and Quality |
-- |
17/06/2026 |
| Dr. Awny Farajallah, M.D. |
Chief Medical Officer |
-- |
17/06/2026 |
| Ms. Natalie Furney |
Global General Counsel |
-- |
17/06/2026 |
| Ms. Nicola Greenway |
Chief Human Resources Officer |
-- |
17/06/2026 |
| Dr. Rhonda Pacheco, PhD |
President, U.S. Business Unit and U.S. Country Head |
-- |
17/06/2026 |
| Mr. Ramy Riad |
President, Plasma-Derived Therapies Business Unit |
-- |
17/06/2026 |
| Ms. Jennifer Smoter |
Chief Communications and Governance Officer |
-- |
17/06/2026 |
|
|
| Mr. Bruce D. Broussard |
Independent Director |
17/06/2026 |
| Dr. John M. Maraganore,PhD |
Independent Director |
17/06/2026 |
| Dr. Steven Gillis, PhD |
Independent Director |
17/06/2026 |
| Dr. Paulus Stoffels, M.D. |
Independent Director |
17/06/2026 |
| Dr. Andrew S. Plump, M.D.,PhD |
Director and President, Research and Development |
17/06/2026 |
| Mr. Milano Furuta |
Director and Chief Financial Officer |
17/06/2026 |
| Ms. Julie Kim |
Chief Executive Officer, President and Director |
17/06/2026 |
| Ms. Kimberly A. Reed |
Independent Director |
17/06/2026 |
| Mr. Masami Iijima |
Chairman of the Board |
17/06/2026 |
| Ms. Miki Tsusaka |
Independent Director |
17/06/2026 |
| Mr. Koichiro Kimura |
Independent Director |
17/06/2026 |
|
|
|
|
